ClinicalTrials.gg
CompletedNCT07110740Updated Aug 8, 2025

Bioequivalence Study Between UI009 and UIC202005 in Healthy Subjects

A Phase 1 interventional study of UI009 and UIC202005 in Health, sponsored by Korea United Pharm. Inc.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by Korea United Pharm. Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Oct 2024, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Evaluate Bioequivalence After Dry-powder Inhalation of UIC202005 or UI009 in Healty Volunteers

02

Conditions studied

  • Health
03

In context

Lead sponsor

Korea United Pharm. Inc. is the lead sponsor of 22 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 19 years or older at the time of screening.
  2. Subjects whose body weight is at least 55 kg and with a (BMI) between 18.0 and 30.0 kg/m².
  3. Subjects confirmed as healthy based on screening tests including vital signs, laboratory tests (hematology, biochemistry, urinalysis), and (ECG), performed within 28 days prior to the first administration of the product.
  4. Female subjects who are not pregnant or breastfeeding, and who do not plan to become pregnant or breastfeed within 7 days after the last administration of the investigational product.
  5. Subjects without congenital or chronic disease, and with no clinical significance based on physical examination.
  6. Subjects who agree not to donate sperm (for males) or ova (for females), and whose partners agree to use medically acceptable from the first administration to 7 days after the last dose.
  7. Subjects able to read and understand a written , and willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any of the following medical histories or conditions deemed by the investigator to potentially interfere with the study:

    • to components of the product or to other drugs such as aspirin or antibiotics
    • Hypersensitivity to sympathomimetic agents
    • hypersensitivity to inhaled lactose (allergic), galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
    • Cardiovascular disorders
    • Infectious respiratory diseases, especially tuberculosis or suspected infectious
    • Moderate to severe bronchiectasis
    • Asthma or COPD requiring emergency treatment
    • Hypokalemia
    • Hepatic dysfunction
    • Hyperthyroidism
    • Seizure disorders
  2. Subjects with a history of taking or currently taking medications deemed by the investigator to potentially interfere with the study

    • Drugs known to interact with the investigational product or related drug classes (e.g., inhibitors, beta-adrenergic agents, catecholamines, , diuretics)
    • Enzyme-inducing or enzyme-inhibiting drugs (e.g., barbiturates) taken within 1 month prior to the first administration of the investigational product
    • Any prescription drugs taken within 10 days prior to the first administration of the investigational product
    • Any over-the-counter medications, including health supplements, herbal medicines, or dietary supplements, taken within 10 days prior to the first administration
  3. Subjects who meet any of the following criteria during screening (including re-tests), and are deemed by the investigator to have findings

    • Systolic blood pressure \< 90 mmHg or > 140 mmHg
    • Diastolic blood pressure \< 55 mmHg or > 90 mmHg
    • (GOT) or ALT (GPT) > 2.0 × upper limit of reference range
    • Serum potassium below the lower limit of the reference range
    • TSH below the lower limit of the reference range
    • or FEV₁/FVC outside the reference range
    • Positive results for serum tests: RPR Ab, Ag/Ab, HBs Ag, Ab
    • Positive result for any drug of abuse in the urine drug screening
  4. Subjects who donated whole blood within 8 weeks, donated blood components within 4 weeks, or received a blood transfusion within 4 weeks prior to the first administration of the investigational product, or who plan to do so during the study period.
  5. Subjects who consumed more than 5 cups/day (1 cup = 250 mL) of grapefruit-containing or caffeine-containing products within 3 months prior to the first administration, or who are unable to abstain from such consumption from 72 hours prior to dosing until the last pharmacokinetic blood sampling of each period.
  6. Subjects who consumed more than 210 g/week of alcohol within 3 months prior to the first administration of the investigational product, or who are unable to abstain from alcohol from 72 hours prior to dosing until the last pharmacokinetic blood sampling of each period.
  7. Subjects who smoked more than 10 cigarettes/day within 3 months prior to the first administration of the investigational product, or who are unable to abstain from smoking from 72 hours prior to dosing until the last pharmacokinetic blood sampling of each period.
  8. Subjects who participated in another clinical trial and received an investigational drug within 6 months prior to the first administration (based on the last dosing date in the previous trial).
  9. Subjects who are unable to consume the standard meals provided by the study center.
  10. Subjects who are deemed by the investigator to be otherwise unsuitable for participation in the study for reasons not covered by the above exclusion criteria.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    UI009

    Drug: UI009

  • Active comparator
    UIC202005

    Drug: UIC202005

Interventions

  • DrugUI009

    inhale UI009 twice a day on Day 1 and Day 8.

  • DrugUIC202005

    inhale UIC202005 twice a day on Day 1 and Day 8.

06

What researchers measure

Primary outcomes

  1. Cmax of Fluticasone propionate

    Cmax(maxium concentration)

    Time frame: Day 1 and Day 8: 0, 0.017, 0.033, 0.067, 0.1, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 hr

  2. AUClast of Fluticasone propionate

    Area under the curve to the last measurable concentration

    Time frame: Day1 and Day8: 0, 0.017, 0.033, 0.067, 0.1, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36hr

  3. AUC0.5hr of Salmeterol

    Area under the curve from time 0 to 0.5 hours

    Time frame: Day1 and Day8: 0, 0.17, 0.033, 0.067, 0.1, 0.167, 0.333, 0.5hr

  4. AUClast of salmeterol

    Area under the curve to the last measurable concentration

    Time frame: Day1 and Day8: 0, 0.017, 0.033, 0.067, 0.1, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36hr

  5. Cmax of Salmeterol

    Cmax(maxium concentration)

    Time frame: Day1 and Day8: 0, 0.017, 0.033, 0.067, 0.1, 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36hr

07

Study locations

1 site
  • Chungnam National University Hospital
    Daejeon, Daejeon 35015, South Korea
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Nov 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Aug 8, 2025
StartActual
Oct 24, 2024
Primary completionActual
Nov 29, 2024
CompletionActual
Dec 13, 2024
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07110740
Responsible party
Sponsor
First posted
Aug 8, 2025
Start date
Oct 24, 2024
Primary completion
Nov 29, 2024
Completion
Dec 13, 2024
Last update
Aug 8, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion